Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + temozolomide + radiotherapy in post-resection glioblastoma (Phase II)
ChiCTR2600126264Phase 2Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in glioblastoma (GBM), sponsored by Foshan First People's Hospital. Primary endpoint: Median progression-free survival (mPFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600126264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126264.